keyword
MENU ▼
Read by QxMD icon Read
search

Antithrombotic therapy

keyword
https://www.readbyqxmd.com/read/29916838/simvastatin-reverses-multiple-myeloma-serum-induced-prothrombotic-phenotype-in-endothelial-cells-via-erk-1-2-signalling-pathway
#1
Rujiao Dong, Guibo Ma, Shunji Zhang, Yujuan Gao, Shuchuan Liu, Yanhua Su
: The introduction of new agents in multiple myeloma therapy has increased the overall response rate and improved clinical outcomes, but the increased risk of thrombotic complications impairs the quality of life of patient and the optimal thromboprophylaxis remains unknown. Increasing evidence has shown that statins can prevent venous thrombosis. Hence, we investigated the effects of simvastatin on multiple myeloma serum-related haemostatic imbalance in endothelial cells in vitro. The effects of simvastatin on procoagulant and anticoagulant protein expression were assessed on mixed multiple myeloma serum-treated human umbilical vein endothelial cells (HUVECs)...
June 18, 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29915905/antithromboembolic-strategies-for-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention
#2
REVIEW
Ayesha Ather, Benjamin Laliberte, Brent N Reed, Ashley Schenk, Kristin Watson, Sandeep Devabhakthuni, Vincent Y See
We set out to synthesize available data on antithrombotic strategies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), with a focus on triple antithrombotic therapy (triple therapy [TT]; dual antiplatelet therapy plus an anticoagulant) versus dual therapy (DT; one antiplatelet agent and an anticoagulant). We searched OVID MEDLINE and PubMed from January 2005 to September 2017 using the search terms oral anticoagulant, triple therapy, dual therapy, acute coronary syndrome, percutaneous coronary intervention, and atrial fibrillation (limited to randomized controlled trials, observational studies, English language, minimum 6-12 months of follow-up, minimum 100 human patients)...
June 19, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29914560/predictive-factors-of-intracranial-bleeding-in-head-trauma-patients-receiving-antiplatelet-therapy-admitted-to-an-emergency-department
#3
Farès Moustafa, Jean Roubin, Bruno Pereira, Alain Barres, Jennifer Saint-Denis, Christophe Perrier, Marine Mondet, Frederic Dutheil, Jeannot Schmidt
BACKGROUND: In head trauma cases involving antiplatelet agent treatment, the French Society of Emergency Medicine recommends performing computed tomography (CT) scans to detect brain lesions, 90% of which are normal. The value of CT is still debatable given the scarce number of studies and controversial results. METHODS: We used the RATED registry (Registry of patient with Antithrombotic agents admitted to an Emergency Department, NCT02706080) to assess factors of cerebral bleeding related to antiplatelet agents following head trauma...
June 19, 2018: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
https://www.readbyqxmd.com/read/29910193/closure-anticoagulation-or-antiplatelet-therapy-for-cryptogenic-stroke-with-patent-foramen-ovale-systematic-review-of-randomized-trials-sequential-meta-analysis-and-new-insights-from-the-close-study
#4
REVIEW
Guillaume Turc, David Calvet, Patrice Guérin, Marjorie Sroussi, Gilles Chatellier, Jean-Louis Mas
BACKGROUND: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing patent foramen ovale (PFO) closure, anticoagulation, and antiplatelet therapy to prevent stroke recurrence in patients with PFO-associated cryptogenic stroke. METHODS AND RESULTS: We searched Medline, Cochrane Library, and EMBASE through March 2018. The primary outcome was stroke recurrence. Pooled incidences, hazard ratios, and risk ratios (RRs) were calculated in random-effects meta-analyses...
June 17, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29908761/health-related-quality-of-life-after-bleeding-adverse-events-associated-with-antithrombotic-drug-therapy-a-systematic-review
#5
REVIEW
Lodewijk C S Res, Bart Lubberts, Shivesh H Shah, Christopher W DiGiovanni
BACKGROUND: Little is known about the health-related quality of life (HRQOL) following adverse bleeding events associated with antithrombotic drug therapy. This systematic review assesses the HRQOL of patients who suffered a bleeding event related to antithrombotic drug use. METHODS: Literature search was performed using PubMed, EMBASE, and the Cochrane Library from inception through June 16, 2017. Studies measuring HRQOL after a bleeding event related to antithrombotic drug therapy for primary or secondary prevention of a thromboembolic event were included...
June 14, 2018: Hellenic Journal of Cardiology: HJC, Hellēnikē Kardiologikē Epitheōrēsē
https://www.readbyqxmd.com/read/29904963/experience-of-a-single-center-in-the-conservative-approach-of-20-consecutive-cases-of-asymptomatic-extracranial-carotid-artery-aneurysms
#6
V E C Pourier, J C Welleweerd, L J Kappelle, G J E Rinkel, Y M Ruigrok, H B van der Worp, T H Lo, M L Bots, F L Moll, Gert J de Borst
BACKGROUND: The clinical course and optimal treatment strategy for asymptomatic aneurysms of the extracranial carotid artery (ECAA) are unknown. We report our single-center experience with conservative management of patients with an asymptomatic ECAA. METHODS: A search in our hospital records from 1998 to 2013 revealed 20 patients (mean age 52 years, SD 12.5) with 23 ECAA, defined as a 150% or more fusiform dilation or any saccular dilatation compared to the healthy internal carotid artery...
June 14, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29901447/long-term-effectiveness-and-safety-of-transcatheter-closure-of-patent-foramen-ovale-compared-with-antithrombotic-therapy-a-meta-analysis-of-6-randomised-clinical-trials-and-3560-patients-with-reconstructed-time-to-event-data
#7
Daniele Giacoppo, Nicola Caronna, Antonio H Frangieh, Jonathan Michel, Giuseppe Andò, Giuseppe Tarantini, Albert M Kasel, Davide Capodanno, Robert A Byrne
AIMS: Although three recent trials showed a significant stroke risk reduction after tPFOc, the impact on pooled evidence deserves attention and individual statistical power is limited. We aimed to pool available randomised clinical trials (RCT) to assess whether tPFOc is more effective and safe than antithrombotic therapy alone (ATA). METHODS AND RESULTS: Major electronic databases and tangential sources were searched and 6 trials (3560 patients) identified. At a median follow-up of 3...
June 12, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29898848/oral-anti-xa-anticoagulation-after-trans-aortic-valve-implantation-for-aortic-stenosis-the-randomized-atlantis-trial
#8
Jean-Philippe Collet, Sergio Berti, Angel Cequier, Eric Van Belle, Thierry Lefevre, Pascal Leprince, Franz-Josef Neumann, Eric Vicaut, Gilles Montalescot
BACKGROUND: Antithrombotic treatment regimen following transcatheter aortic valve replacement (TAVR) is not evidence-based. Apixaban, a non-vitamin K direct anticoagulant (NOAC) was shown to be superior to VKA and superior to aspirin to prevent cardioembolic stroke in non-valvular atrial fibrillation. It may have the potential to reduce TAVR-related thrombotic complications including subclinical valve thrombosis along with a better safety than the standard of care. DESIGN: ATLANTIS is a multicenter, randomized, phase IIIb, prospective, open-label, superiority study comparing standard of care (SOC Group) versus an apixaban-based strategy (Anti-Xa Group) after successful TAVR (ClinicalTrials...
June 2018: American Heart Journal
https://www.readbyqxmd.com/read/29898844/an-open-label-2-%C3%A3-2-factorial-randomized-controlled-trial-to-evaluate-the-safety-of-apixaban-vs-vitamin-k-antagonist-and-aspirin-vs-placebo-in-patients-with-atrial-fibrillation-and-acute-coronary-syndrome-and-or-percutaneous-coronary-intervention-rationale
#9
Renato D Lopes, Amit N Vora, Danny Liaw, Christopher B Granger, Harald Darius, Shaun G Goodman, Roxana Mehran, Stephan Windecker, John H Alexander
BACKGROUND: The optimal antithrombotic strategy for patients with atrial fibrillation (AF) who develop acute coronary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events. DESIGN: AUGUSTUS is an international, multicenter randomized trial with a 2 × 2 factorial design to compare apixaban with vitamin K antagonists and aspirin with placebo in patients with AF who develop ACS and/or undergo PCI and are receiving a P2Y12 inhibitor...
June 2018: American Heart Journal
https://www.readbyqxmd.com/read/29887934/inhibition-of-high-shear-arterial-thrombosis-by-charged-nanoparticles
#10
Michael T Griffin, Yuanzheng Zhu, Zixiang Liu, Cyrus K Aidun, David N Ku
Platelet accumulation under high shear rates at the site of atherosclerotic plaque rupture leads to myocardial infarction and stroke. Current antiplatelet therapies remain ineffective within a large percentage of the population, while presenting significant risks for bleeding. We explore a novel way to inhibit arterial thrombus formation by biophysical means without the use of platelet inactivating drugs. Our computational multi-scale dynamics model has predicted that charged particles of a specific size may entangle von Willebrand Factor (vWF) polymers and reduce the amount of elongation at high shear rates...
July 2018: Biomicrofluidics
https://www.readbyqxmd.com/read/29887180/perioperative-and-periprocedural-management-of-antithrombotic-therapy-consensus-document-of-sec-sedar-seacv-sectcv-aec-secpre-sepd-sego-sehh-seth-semergen-semfyc-semg-semicyuc-semi-semes-separ-senec-seo-sepa-servei-secot-and-aeu
#11
David Vivas, Inmaculada Roldán, Raquel Ferrandis, Francisco Marín, Vanessa Roldán, Antonio Tello-Montoliu, Juan Miguel Ruiz-Nodar, Juan José Gómez-Doblas, Alfonso Martín, Juan Vicente Llau, María José Ramos-Gallo, Rafael Muñoz, Juan Ignacio Arcelus, Francisco Leyva, Fernando Alberca, Raquel Oliva, Ana María Gómez, Carmen Montero, Fuat Arikan, Luis Ley, Enrique Santos-Bueso, Elena Figuero, Antonio Bujaldón, José Urbano, Rafael Otero, Juan Francisco Hermida, Isabel Egocheaga, José Luis Llisterri, José María Lobos, Ainhoa Serrano, Olga Madridano, José Luis Ferreiro
During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios...
June 7, 2018: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29886715/recent-advances-in-primary-and-secondary-prevention-of-atherosclerotic-stroke
#12
Georgios Tsivgoulis, Apostolos Safouris, Dong-Eog Kim, Andrei V Alexandrov
Atherosclerosis is a major cause of ischemic stroke that can be effectively prevented with appropriate lifestyle modifications and control of cardiovascular risk factors. Medical advances in recent years along with aggressive cardiovascular risk factor modifications have resulted in decreased recurrence rates of atherosclerotic stroke. Non-statin lipid-lowering molecules have recently shown clinical benefit and are recommended for very high-risk patients to reduce their risk of stroke. Aggressive hypertension treatment is crucial to reduce atherosclerotic stroke risk...
May 2018: Journal of Stroke
https://www.readbyqxmd.com/read/29884748/a-function-blocking-par4-antibody-is-markedly-antithrombotic-in-the-face-of-a-hyperreactive-par4-variant
#13
Shauna L French, Claudia Thalmann, Paul F Bray, Lynn E Macdonald, Andrew J Murphy, Mark W Sleeman, Justin R Hamilton
Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However, a common sequence variant in human PAR4 (rs773902, encoding Thr120 in place of Ala120) renders the receptor more sensitive to agonists and less sensitive to antagonists. Here, we develop the first human monoclonal function-blocking antibody to human PAR4 and show it provides equivalent efficacy against the Ala120 and Thr120 PAR4 variants...
June 12, 2018: Blood Advances
https://www.readbyqxmd.com/read/29880555/elevated-plasma-d-dimer-level-is-associated-with-short-term-risk-of-ischemic-stroke-in-patients-with-acute-heart-failure
#14
Yasuhiro Hamatani, Toshiyuki Nagai, Michikazu Nakai, Kunihiro Nishimura, Yasuyuki Honda, Hiroki Nakano, Satoshi Honda, Naotsugu Iwakami, Yasuo Sugano, Yasuhide Asaumi, Takeshi Aiba, Teruo Noguchi, Kengo Kusano, Kazunori Toyoda, Satoshi Yasuda, Hiroyuki Yokoyama, Hisao Ogawa, Toshihisa Anzai
BACKGROUND AND PURPOSE: The incidence of heart failure increases the subsequent risk of ischemic stroke, and its risk could be higher in the short-term period after an acute heart failure (AHF) event. However, its determinants remain to be clarified. Plasma D-dimer level reflects fibrin turnover and exhibits unique properties as a biomarker of thrombosis. The aim of this study is to investigate whether D-dimer level is a determinant of short-term incidence of ischemic stroke in patients with AHF...
June 7, 2018: Stroke; a Journal of Cerebral Circulation
https://www.readbyqxmd.com/read/29877660/efficacy-and-safety-of-oral-anticoagulant-therapy-in-frail-patients-with-atrial-fibrillation
#15
Giuseppe Patti, Ludmilla Mantione, Edoardo Bressi, Antonio Bisignani
Antithrombotic treatment of frail patients with AF presents various challenges. The fear of bleeding often leds to a large underuse of anticoagulant agents in these patients, although more recent data indicate that oral anticoagulation  (especially with the newer, direct anticoagulants) is increasingly used. While there is a need for more real world data, available evidence suggests that non-vitamin K antagonist oral anticoagulants (NOACs) are an effective alternative to warfarin in frail patients with AF for preventing thromboembolic events, with a better safety profile...
June 7, 2018: Monaldi Archives for Chest Disease, Archivio Monaldi Per le Malattie del Torace
https://www.readbyqxmd.com/read/29871683/transient-portal-vein-thrombosis-in-liver-cirrhosis
#16
REVIEW
Xingshun Qi, Xiaozhong Guo, Eric M Yoshida, Nahum Méndez-Sánchez, Valerio De Stefano, Frank Tacke, Andrea Mancuso, Yasuhiko Sugawara, Sien-Sing Yang, Rolf Teschke, Ankur Arora, Dominique-Charles Valla
In real-world clinical practice, the acceptance of anticoagulation therapy in the management of portal vein thrombosis (PVT) in patients with cirrhosis is limited by the fear of an increased bleeding risk. Additionally, accumulating evidence indicates that spontaneous recanalization of PVT may occur in the absence of antithrombotic treatment. Therefore, risk stratification based on outcomes in such patients is crucial for determining a therapeutic strategy. In this paper, we draw attention to the distinct clinical entity, "transient PVT" by introducing two cases with PVT that spontaneously recanalized in the absence of antithrombotic treatment...
June 5, 2018: BMC Medicine
https://www.readbyqxmd.com/read/29866816/activated-protein-c-protease-activated-receptor-1-and-neuroprotection
#17
John H Griffin, Berislav V Zlokovic, Laurent O Mosnier
Protein C is a plasma serine protease zymogen whose active form, activated protein C (APC), exerts potent anticoagulant activity. In addition to its antithrombotic role as a plasma protease, pharmacologic APC is a pleiotropic protease that activates diverse homeostatic cell signaling pathways via multiple receptors on many cells. Engineering of APC by site-directed mutagenesis provided a signaling selective APC mutant with 3 Lys residues replaced by 3 Ala residues, 3K3A-APC, that lacks > 90 % anticoagulant activity but retains normal cell signaling activities...
June 4, 2018: Blood
https://www.readbyqxmd.com/read/29866813/extravascular-coagulation-in-hematopoietic-stem-and-progenitor-cell-regulation
#18
T Son Nguyen, Tsvee Lapidot, Wolfram Ruf
The hemostatic system plays pivotal roles in injury repair, innate immunity and adaptation to inflammatory challenges. We here review the evidence that these vascular protective mechanisms have non-traditional roles in hematopoietic stem cell (HSC) maintenance in their physiological bone marrow (BM) niches at steady state and under stress. Expression of coagulation factors and the extrinsic coagulation initiator tissue factor by osteoblasts, tissue resident macrophages and megakaryocytes suggests that endosteal as well as vascular HSC niches are functionally regulated by extravascular coagulation...
June 4, 2018: Blood
https://www.readbyqxmd.com/read/29864774/inherited-thrombophilia-and-pregnancy-complications-should-we-test
#19
Deepa R J Arachchillage, Mike Makris
Recurrent miscarriages and pregnancy-related complications cause significant stress to couples looking for successful pregnancy outcome as well as to health care professionals. There is conflicting evidence with respect to the presence and the strength of associations between inherited thrombophilia and these complications. A complete thrombophilia screen is expensive, and no proven effective treatment for women with recurrent miscarriage and inherited thrombophilia is currently available. Based on the concept of microvascular thrombosis of the placenta, women with recurrent miscarriage and placenta-related complications frequently get treated with antithrombotic therapy...
June 4, 2018: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/29861295/stroke-prevention-1-year-clinical-outcomes-and-healthcare-resource-utilization-in-patients-with-atrial-fibrillation-in-france-data-from-the-garfield-af-registry
#20
Jean-Yves Le Heuzey, Jean-Pierre Bassand, Jean-Baptiste Berneau, Paolo Cozzolino, Lucia D'Angiolella, Bernard Doucet, Lorenzo G Mantovani, Michel Martelet, Joseph Mouallem, Jean-Joseph Muller, Karen Pieper
BACKGROUND: GARFIELD-AF is a non-interventional worldwide study of adults with atrial fibrillation. AIMS: To analyse the characteristics of the 1399 patients recruited in France from August 2010 to July 2015, their 1-year outcomes and healthcare resource utilization. METHOD: Patients aged ≥18 years with newly diagnosed atrial fibrillation (≤6 weeks' duration) and ≥1 stroke risk factor were eligible. Patient demographics, medical history and antithrombotic treatment were recorded at baseline...
May 31, 2018: Archives of Cardiovascular Diseases
keyword
keyword
12182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"